Want to see LBRX full AI Analyst Report?
Top Page
LB Pharmaceuticals, Inc.
(NASDAQ:LBRX)
Select Model
Select Model
Rating:48Neutral
Price Target:
$41.00
▼(-12.95% Downside)
Action:Reiterated
Date:10/16/26
The score is held back primarily by weak financial performance (no revenue, continued losses, and cash burn) and bearish technical momentum. Offsetting this, corporate events are notably positive—fresh financing, accelerated Phase 3 timeline, and strengthened leadership—while valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Strengthened balance sheet
The sharp improvement in equity and very low leverage provide greater financial flexibility than in prior years. This stronger solvency position can support continued clinical investment and reduce near-term balance-sheet pressure while the company advances toward potential product commercialization.
Negative Factors
No revenue traction
The absence of revenue means the business has not yet demonstrated commercial demand or an internally funded operating model. Until a product generates sales, progress remains dependent on clinical success and continued access to capital, leaving earnings power unproven over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened balance sheet
The sharp improvement in equity and very low leverage provide greater financial flexibility than in prior years. This stronger solvency position can support continued clinical investment and reduce near-term balance-sheet pressure while the company advances toward potential product commercialization.
Read all positive factors
LB Pharmaceuticals, Inc. (LBRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.27B
Dividend YieldN/A
Average Volume (3M)424.48K
Price to Earnings (P/E)―
Beta (1Y)1.55
Revenue GrowthN/A
EPS Growth-132.05%
CountryUS
Employees49
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.97
Shares Outstanding32,259,174
10 Day Avg. Volume449,593
30 Day Avg. Volume424,482
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-15.97
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.66K
Enterprise Value/Ebitda-7.48
Forecast
1Y Price Target
$61.44Price Target Upside30.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.65
Revenue Forecast (FY)N/A
LB Pharmaceuticals, Inc. Business Overview & Revenue Model
Company Description
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, th...
How the Company Makes Money
null...
LB Pharmaceuticals, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -179.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -87.65M | -24.88M | -63.01M | -1.45M | -12.19M |
| Net Income | -85.69M | -25.20M | -63.10M | -6.28M | -14.35M |
Balance Sheet | |||||
| Total Assets | 361.69M | 312.93M | 33.53M | 45.66M | 21.49M |
| Cash, Cash Equivalents and Short-Term Investments | 327.79M | 295.21M | 28.00M | 43.29M | 21.40M |
| Total Debt | 5.22M | 3.57M | 3.70M | 0.00 | 24.15M |
| Total Liabilities | 29.34M | 11.62M | 128.09M | 80.13M | 50.30M |
| Stockholders Equity | 332.35M | 301.31M | -94.55M | -34.47M | -28.81M |
Cash Flow | |||||
| Free Cash Flow | -82.83M | -35.26M | -53.82M | -12.12M | -2.73M |
| Operating Cash Flow | -82.39M | -35.21M | -53.05M | -12.09M | -2.73M |
| Investing Cash Flow | -44.82M | -39.89M | 23.23M | -28.01M | 123.00K |
| Financing Cash Flow | 396.37M | 302.56M | 38.31M | 33.68M | 22.96M |
LB Pharmaceuticals, Inc. Technical Analysis
Positive
47.10
Price Trends
42.01
Negative
38.46
Positive
32.17
Positive
Market Momentum
-0.43
Negative
52.14
Neutral
68.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LBRX, the sentiment is Positive. The current price of 47.1 is above the 20-day moving average (MA) of 36.97, above the 50-day MA of 42.01, and above the 200-day MA of 32.17, indicating a neutral trend. The MACD of -0.43 indicates Negative momentum. The RSI at 52.14 is Neutral, neither overbought nor oversold. The STOCH value of 68.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LBRX.
LB Pharmaceuticals, Inc. Risk Analysis
LB Pharmaceuticals, Inc. disclosed 86 risk factors in its most recent earnings report. LB Pharmaceuticals, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LB Pharmaceuticals, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
LBRX
LB Pharmaceuticals, Inc.
39.64
23.07
139.23%
HIND
Vyome Holdings
1.70
-3.83
-69.26%
ENVB
Enveric Biosciences
1.42
-5.70
-80.06%
PBM
Psyence Biomedical
3.01
-17.74
-85.49%
SPRC
SciSparc Ltd.
0.85
-32.27
-97.43%
LB Pharmaceuticals, Inc. Corporate Events
Business Operations and StrategyExecutive/Board Changes
LB Pharmaceuticals Appoints Susan Kozauer as Chief Medical Officer
Positive
Sep 15, 2026
On September 15, 2026, LB Pharmaceuticals announced the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer, effective September 14, 2026, underscoring a strategic leadership move in neuropsychiatric drug development. Kozauer, an exper...
Business Operations and StrategyExecutive/Board Changes
LB Pharmaceuticals Appoints Joseph Miller as New CFO
Positive
Sep 3, 2026
On September 3, 2026, LB Pharmaceuticals announced that Joseph M. Miller had been appointed Chief Financial Officer, effective September 2, 2026, bringing over 20 years of biopharmaceutical finance and operational experience to the neuromedicines ...
Business Operations and StrategyPrivate Placements and Financing
LB Pharmaceuticals Announces $150 Million Private Placement Financing
Positive
Jul 29, 2026
On July 28, 2026, LB Pharmaceuticals Inc. entered into a securities purchase agreement for a $150 million private placement of 3,577,560 common shares and pre-funded warrants for up to 715,513 additional shares, sold to a limited group of institut...
Business Operations and StrategyProduct-Related Announcements
LB Pharmaceuticals accelerates Phase 3 schizophrenia trial timeline
Positive
Jul 22, 2026
On July 22, 2026, LB Pharmaceuticals announced that faster-than-expected enrollment in its pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia will allow it to deliver topline results in the first half of 2027, earlier than its prior guidance ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.